This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Kerendia Banner

ESC 2026 Heart Failure Guidelines

Kerendia is supported by the 2026 ESC HF guidelines as a foundational medical therapy with a Class IA recommendation in HFpEF, on par with SGLT2i1

The 2026 European Society of Cardiology (ESC) Heart Failure Guidelines represent an important evolution in the treatment of heart failure. 

For the first time, mineralocorticoid receptor antagonists (MRAs) are recognised as foundational medical therapy and receive a Class I, Level A recommendation for HFpEF, reinforcing the importance of mineralocorticoid receptor blockade in contemporary heart failure management.1

A New Foundation for Heart Failure Care 

The latest ESC guidelines position MRA therapy alongside other evidence-based treatments as part of a foundational approach to managing heart failure.  

 

Why Kerendia? 

Kerendia® (finerenone) is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) with a distinct pharmacological profile from traditional steroidal MRAs. 

Kerendia® (finerenone) is the first and only mineralocorticoid receptor antagonist (MRA) licensed for the treatment of symptomatic chronic heart failure with LVEF ≥40% in adults.2

ESC Guidelines HF 2026
2026 ESC HF guidelines2
2026 ESC guidelines

The latest ESC guidelines reinforce the importance of earlier, evidence-based intervention, recognising MRA therapy as a foundational component of heart failure care. As heart failure care continues to evolve, the goal remains unchanged: helping more patients achieve better outcomes, experience fewer hospitalisations and enjoy a better quality of life. 

 

CV=cardiovascular; ESC=European Society of Cardiology; HF=heart failure; HFmrEF=heart failure with mildy reduced ejection fraction HF LVEF=heart failure with left ventricular ejection fraction; HFpEF=heart failure with preserved ejection fraction; LVEF=left ventricular ejection fraction; MR=mineralocorticoid receptor; nsMRA=non-steroidal mineralocorticoid receptor antagonist; SGLT2i=sodium-glucose cotransporter 2 inhibitor; WHF=Worsening Heart Failure; FMT= Foundational Medical Therapy; HFH= Heart Failure Hospitalisation; ACC, American College of Cardiology; AHA, American Heart Association; 

 References: 

  1. Køber L, et al. Eur Heart J. Published online August 28, 2026. doi:10.1093/eurheartj/ ehag100. 
  2. Solomon SD, et al. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 
  3. AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026) 
  4. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure(v0.1) 
  5. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

 Kerendia▼(finerenone) Prescribing Information

PP-KER-GB-1080 | October 2026